Status:
COMPLETED
Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis
Lead Sponsor:
WellSpan Health
Conditions:
Kidney Stone
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Tamsulosin (Flowmax)is approved by the FDA for the treatment for enlarged prostate. Several studies regarding the use of Tamsulosin for the treatment of lower kidney stones have been carried out in th...
Eligibility Criteria
Inclusion
- 18 y.o. or older
- diagnosed with a kidney stone less than or equal to 10 mm determined by CT scan
- physician has made the decision that you will be discharged to home
- must be able to take study medication for up to 10 days and strain your urine
- must be able to keep a record of pain medication taken and complete a pain scale rating
Exclusion
- patients currently taking: Tamsulosin (Flowmax), calcium channel blockers, beta blockers, alpha blockers, Sildenaphil (Viagara), Tadalaphil (Cilias), Warfarin (Coumadin, Jantoven), Cimetidine (Tagamet, Tagamet HB)
- patients with a clinical and laboratory signs of: urinary tract infection, multiple kidney stones, diabetes, kidney failure, hypotension, pregnancy, fever
- patient known to have hypersensitivity to Tamsulosin
- patient history of cataract surgery
- inability of patient to perform visual pain scale
- allergy or intolerance to acetaminophen/oxycodone
- patient is unable to understand informed consent
- prisoners
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT00762424
Start Date
June 1 2007
End Date
January 1 2011
Last Update
December 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
York Hospital Emergency Department
York, Pennsylvania, United States, 17405